摘要
Cancer is a complex disease,and despite incredible progress over the last decade,it remains the leading cause of death worldwide.Liver cancers,including hepatocellular carcinoma(HCC),and liver metastases are distinct from other cancers in that they typically emerge as a consequence of long-term low-grade inflammation.Understanding the mechanisms that underpin inflammation-driven tissue remodeling of the hepatic immune environment is likely to provide new insights into much needed treatments for this devastating disease.Group 1 innate lymphoid cells(ILCs),which include natural killer(NK)cells and ILC1s,are particularly enriched in the liver and thought to contribute to the pathogenesis of a number of liver diseases,including cancer.NK cells are an attractive,but underexplored,therapeutic target in hepatic disease due to their role in immunosurveillance and their ability to recognize and eliminate malignant cells.ILC1s are closely related to and share many phenotypic features with NK cells but are less well studied.Thus,their utility in immunotherapeutic approaches is not yet well understood.Here,we review our current understanding of ILCs in cancer with a particular focus on liver and liver-related diseases.
基金
Open Access funding enabled and organized by CAUL and its Member Institutions.
